Vitamin D

VitD3 Supplementation in Patients With Multiple Myeloma

What's the purpose of the trial?

The goal of this clinical trial is to evaluate post-transplant immune reconstitution and lymphocyte recovery as well as the 3-year progression-free survival of patients with multiple myeloma in two treatment arms. 

Trial status

Not yet accepting

Phase
Phase 1
Enrollment
100
Last Updated
2 weeks ago
Patient Screener

Participating Centers

There is one center participating in this trial. Enter a location below to view the distance.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Lenalidomide is an oral immunomodulatory drug that may help the immune system kill cancer cells. It may also prevent the growth of new blood vessels that tumors need to grow.
  • Vitamin D is a vitamin that helps many different essential functions in our body. Researchers are studying whether supplementing vitamin D during treatment can help improve patient outcomes.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not yet accepting

Lenalidomide + Intensified Vitamin D

Not yet accepting

Lenalidomide + Therapeutic Vitamin D

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.